heart muscle patch (BioVAT)
Jump to navigation
Jump to search
Indications
- symptomatic left ventricular systolic dysfunction (HFrEF)
Procedure
- epicardially transplantation of engineered heart muscle composed of cardiomyocytes & stromal cells derived from allogeneic induced pluripotent stem cells
More general terms
References
- ↑ Lou N Dawn of Heart Muscle Patches to Address Lost Myocardium in Heart Failure. Early report on modular BioVAT patches in advanced stage C or D disease. MedPage Today. May 27, 2026 https://www.medpagetoday.com/transplantation/hearttransplantation/121455
Zimmermann WH, Ensminger S, Kutschka I, et al for the BioVAT-HF Investigators. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. 2026 May 28;394(20):1991-2001. PMID: https://pubmed.ncbi.nlm.nih.gov/42202318 Clinical Trial. https://www.nejm.org/doi/full/10.1056/NEJMoa2513525
Margulies KB. Patching Up Damaged Hearts. N Engl J Med. 2026 May 28;394(20):2054-2055. PMID: https://pubmed.ncbi.nlm.nih.gov/42202326 https://www.nejm.org/doi/full/10.1056/NEJMe2601225
Srivastava D. Remuscularizing the Failing Human Heart. N Engl J Med. 2026 May 28;394(20):2055-2058. PMID: https://pubmed.ncbi.nlm.nih.gov/42202327 https://www.nejm.org/doi/full/10.1056/NEJMe2601013